工作
发表于 2025-3-26 22:45:25
http://reply.papertrans.cn/44/4303/430214/430214_31.png
Bureaucracy
发表于 2025-3-27 04:13:58
http://reply.papertrans.cn/44/4303/430214/430214_32.png
Sarcoma
发表于 2025-3-27 06:31:25
http://reply.papertrans.cn/44/4303/430214/430214_33.png
招待
发表于 2025-3-27 13:29:49
When Is an In Silico Representation a Digital Twin? A Biopharmaceutical Industry Approach to the Di a brief retrospect on their history and expectations for their deployment in today’s business environment, and a detailed financial assessment of their attractive economic benefits are provided in this chapter. The argument that restrictive guidelines set forth by regulatory agencies would hinder t
BACLE
发表于 2025-3-27 14:26:13
E. M. R. Critchley,A. A. Eisen waste management. The Japan Atomic Energy Agency (JAEA) proposes the transmutation of minor actinides by an accelerator-driven system (ADS) using lead–bismuth eutectic alloy (Pb-Bi) as a spallation target and a coolant of the subcritical core. The current ADS design has 800 MWth of rated power, whi
刺耳
发表于 2025-3-27 20:09:40
Tab. 6.1 gibt nur In-vitro-Empfindlichkeiten bzw. Resistenzen an (+ = empfindlich, ± = intermediär, 0 = resistent). In-vitro-Empfindlichkeit bedeutet nicht automatisch auch In-vivo-Wirksamkeit. Die in vivo, also beim Patienten wirksamen Antibiotika sind im nächsten Kapitel zusammengestellt.